Literature DB >> 27318333

Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents.

Nicholas W Van Hise1, Alex M Bryant2, Erin K Hennessey3, Andrew J Crannage3, Jad A Khoury4, Farrin A Manian5.   

Abstract

We compared rates of recurrent Clostridium difficile infection in patients receiving or not receiving oral vancomycin prophylaxis with systemic antimicrobial therapy. The incidence of C. difficile infection was significantly lower in patients receiving prophylaxis (4.2% vs 26.6% in those without prophylaxis; odds ratio, 0.12; 95% confidence interval, .04-.4; P < .001).
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  Clostridium difficile; antimicrobial agents; prophylaxis; vancomycin

Mesh：

Substances：

Year:  2016        PMID： 27318333     DOI： 10.1093/cid/ciw401

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  16 in total

1.  47-Year-Old Man With Abdominal Pain and Diarrhea.

Authors:  Don Chamil Codipilly; Victor Chedid; Arthur Beyder
Journal:  Mayo Clin Proc       Date:  2017-11-13       Impact factor: 7.616

2.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

Authors:  L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

3.  Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections.

Authors:  Alex Carignan; Sébastien Poulin; Philippe Martin; Annie-Claude Labbé; Louis Valiquette; Hamed Al-Bachari; Louis-Philippe Montpetit; Jacques Pépin
Journal:  Am J Gastroenterol       Date:  2016-09-13       Impact factor: 10.864

4.  Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients.

Authors:  Alex Ganetsky; Jennifer H Han; Mitchell E Hughes; Daria V Babushok; Noelle V Frey; Saar I Gill; Elizabeth O Hexner; Alison W Loren; Selina M Luger; James K Mangan; Mary Ellen Martin; Jacqueline Smith; Craig W Freyer; Cheryl Gilmar; Mindy Schuster; Edward A Stadtmauer; David L Porter
Journal:  Clin Infect Dis       Date:  2019-05-30       Impact factor: 9.079

5.  Cost-effectiveness of Treatment Regimens for Clostridioides difficile Infection: An Evaluation of the 2018 Infectious Diseases Society of America Guidelines.

Authors:  Radha Rajasingham; Eva A Enns; Alexander Khoruts; Byron P Vaughn
Journal:  Clin Infect Dis       Date:  2020-02-14       Impact factor: 9.079

6.  Management of Recurrent Clostridium difficile Infection During Intensive Chemotherapy and Stem Cell Transplantation for Leukemia: Case with Literature Review.

Authors:  Umar Zahid; Fnu Sagar; Mayar Al Mohajer; Aneela Majeed
Journal:  Cureus       Date:  2018-04-02

7.  Analysis of the impact of secondary prophylaxis on Clostridioides difficile recurrence in critically ill adults.

Authors:  Kathryn A Connor; Kelly M Conn
Journal:  SAGE Open Med       Date:  2020-06-12

Review 8.  Clostridioides difficile therapeutics: guidelines and beyond.

Authors:  Robert Orenstein; Roberto L Patron
Journal:  Ther Adv Infect Dis       Date:  2019-08-13

Review 9.  Critical Care Management of the Patient with Clostridioides difficile.

Authors:  Max W Adelman; Michael H Woodworth; Virginia O Shaffer; Greg S Martin; Colleen S Kraft
Journal:  Crit Care Med       Date:  2021-01-01       Impact factor: 9.296

Review 10.  Sleeping with the enemy: Clostridium difficile infection in the intensive care unit.

Authors:  Florian Prechter; Katrin Katzer; Michael Bauer; Andreas Stallmach
Journal:  Crit Care       Date:  2017-10-22       Impact factor: 9.097
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.